Enbrel Shortage Strategies: Clinical Trials Will Provide “Bolus” Of Patients
Executive Summary
Immunex' ongoing Enbrel clinical trials will help provide a "bolus" of patients for the rheumatoid arthritis agent once the company expands its commercial capacity for the biologic
You may also be interested in...
Amgen files Enbrel plant sBLA
Amgen files sBLA Aug. 23 for Enbrel manufacturing facility in Rhode Island. Company expects to begin shipping from the plant immediately after approval, which is projected for first quarter 2003. Rhode Island plant will use same high-yield manufacturing process used at contract manufacturer Boehringer Ingelheim's facility (1"The Pink Sheet" April 29, p. 35). Etanercept shortage continues with 23,000 patients on waiting list as of July 24. Approximately 200,000 potential patients have signed up to receive information on rheumatoid arthritis through Amgen's "RA Access" unbranded TV ad campaign...
Amgen files Enbrel plant sBLA
Amgen files sBLA Aug. 23 for Enbrel manufacturing facility in Rhode Island. Company expects to begin shipping from the plant immediately after approval, which is projected for first quarter 2003. Rhode Island plant will use same high-yield manufacturing process used at contract manufacturer Boehringer Ingelheim's facility (1"The Pink Sheet" April 29, p. 35). Etanercept shortage continues with 23,000 patients on waiting list as of July 24. Approximately 200,000 potential patients have signed up to receive information on rheumatoid arthritis through Amgen's "RA Access" unbranded TV ad campaign...
Abbott D2E7 Monotherapy Use Should Afford Faster FDA Review, Abbott Says
Abbott is focusing on the need for a regular supply of an anti-TNF agent that can be dosed without methotrexate as a justification for requiring a faster review of D2E7 at FDA